ArticlemedRxiv : the preprint server for health sciences2026
No cognitive or psychological impact from returning research Alzheimer disease biomarkers: A delayed-start, noninferiority, randomized clinical trial.
Article in medRxiv : the preprint server for health sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04699786 (Returning Research Results That Indicate Risk of Alzheimer Disease Dementia to Healthy Participants in Longitudinal Studies), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Returning Research Results That Indicate Risk of Alzheimer Disease Dementia to Healthy Participants in Longitudinal Studies: Quantitative Analyses of a Randomized Clinical Trial
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
Importance: Little is known about the impact of returning Alzheimer disease (AD) biomarkers to cognitively unimpaired (CU) research participants. Objective: Determine whether return of research results (RoRR) negatively impacts longitudinal symptoms of depression and cognition. Design: Randomized, noninferiority, delayed-start clinical trial, 2021-2025. Setting: AD biomarker research results offered to CU participants in a longitudinal cohort of community-dwelling older adults. Participants: 341 CU research participants age >65 with available biomarkers ( Interventions for clinical trials or Exposures for observational studies: Participants were offered their research AD biomarker results (RoRR) with an estimated 5-year risk of symptomatic AD. After consenting, participants were randomized to either receiving results within several weeks (RoRR arm) or 1 year later (delayed-start arm). Main Outcomes and Measures: Longitudinal change in Geriatric Depression Scale (GDS), Clinical Dementia Rating Results: 147 participants received results after randomization: 70 in RoRR arm (average age 75, 60% female), 66 in delayed-start arm (average age 73, 53% female). The observed changes in annual measures did not differ between arms in both those with elevated amyloid (Aβ+) and in those without elevated amyloid (Aβ-) for GDS (Aβ+ difference 0.7, 95% CI 0.0-1.3; Aβ- difference -0.1, 95% CI -0.7-0.5; clinically significant decline >4.0), CDR-SB (Aβ+ difference 0.0, 95% CI -0.1-0.1; Aβ- difference 0.0, 95% CI 0.0-0.1; clinically significant decline >0.5), and cognitive composite (Aβ+ difference -0.10, 95% CI -0.25-0.06; Aβ- difference -0.05, 95% CI -0.17-0.07; clinically significant decline < -0.26). Secondary analyses found no evidence of association between RoRR and proximity to follow-up testing. Conclusions and Relevance: In the first randomized, delayed-start clinical trial of returning AD research results to CU older-adult participants, no effect was seen on longitudinal changes in symptoms of depression or cognition. This supports evidence that there are no harms to returning AD research results, although the results may not apply to more diverse populations not included in this study. Trial Registration: NCT04699786.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.